Ultrasound Contrast Agents Should Drop Boxed Warning, Medical Society Tells FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Citizen petition by the International Contrast Ultrasound Society says updated safety data from recent meta-analysis makes black box unnecessary.
You may also be interested in...
Ultrasound Contrast Agent Warnings Remain Boxed, But Less Monitoring Required
FDA rejects a citizen petition requesting removal of the boxed warning in Optison and Definity labeling, but the agency agrees to modified wording to eliminate certain monitoring requirements and include new data, despite misgivings about the quality of the postmarketing studies cited in the petition.
Ultrasound Contrast Agents Need New Safety Trial After Discouraging Advisory Cmte.
An FDA advisory panel member suggests having a third party design future safety studies for ultrasound contrast agents.
FDA Supersizes Its Order For LABA Safety Studies
The trials, which follow a label change and new REMS, will encompass seven times the patients included in the studies submitted to FDA for approval.